GEN Exclusives

More »

BioMarket Trends

More »
May 1, 2010 (Vol. 30, No. 9)

Emerging Vaccines Set to Shake Up Market

Novel Products for Malaria, Diabetes, Addiction, and Others Could Change the Nature of Healthcare

  • West Nile Virus

    With relatively severe symptoms and a lack of standard therapies for care, West Nile Virus represents a significant threat to individuals who have been infected. However, prevalence is relatively low and confined to developing areas. Because of this, research into prophylactics and therapeutics remains limited with public funding and smaller organizations responsible for most of the initiatives.

  • Market Forecast

    The disease areas covered in this article are those most likely to feature approved vaccine products in the near future. As a result of recent advances, it is likely that sales of emerging vaccine products will add $9 billion to the vaccine market in six years, and that these emerging vaccines will add over $24 billion to the vaccine market in 2020. (This is in addition to the $22 billion and growing vaccine market that exists today).

    This projection assumes that a good number of vaccine candidates currently in Phase III will be commercialized in 2012, several candidates in Phase II will enter the market in 2014, and some of the candidates in Phase I will launch in 2016. It is unlikely that all candidates will be approved, but assuming that vaccine candidate failures follow normal historical trends, we predict total sales of emerging vaccines will hit $25 billion in 2020.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »